Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
7.14% $11.86
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 500.35 mill |
EPS: | -3.12 |
P/E: | -3.80 |
Earnings Date: | Mar 10, 2024 |
SharesOutstanding: | 42.19 mill |
Avg Daily Volume: | 0.784 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.80 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.65x |
Company: PE -3.80 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.721 (-85.49%) $-10.14 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 10.92 - 12.80 ( +/- 7.89%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Palleiko Benjamin L | Buy | 250 000 | Restricted Stock Unit |
2024-02-20 | Venrock Healthcare Capital Partners Iii, L.p. | Buy | 655 738 | Pre-Funded Warrants (Right to Buy) |
2024-02-17 | Feener Edward P. | Buy | 18 788 | Common Stock |
2024-02-20 | Feener Edward P. | Sell | 8 397 | Common Stock |
2024-02-20 | Feener Edward P. | Sell | 19 591 | Common Stock |
INSIDER POWER |
---|
65.05 |
Last 99 transactions |
Buy: 3 039 025 | Sell: 648 624 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $11.86 (7.14% ) |
Volume | 2.15 mill |
Avg. Vol. | 0.784 mill |
% of Avg. Vol | 274.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.73 | N/A | Active |
---|
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.